Douglas Woodruff
Psychiatry · Baltimore, MDNPI 1972779023
Payments from drug & device makers
Across 155 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$796
- Otsuka America Pharmaceutical, Inc.$538
- Johnson & Johnson$523
- Sunovion Pharmaceuticals Inc.$434
- Supernus Pharmaceuticals, Inc.$312
- Takeda Pharmaceuticals U.S.A., Inc.$306
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,360100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $796 |
| Otsuka America Pharmaceutical, Inc. | 7 | $538 |
| Johnson & Johnson | 10 | $523 |
| Sunovion Pharmaceuticals Inc. | 17 | $434 |
| Supernus Pharmaceuticals, Inc. | 6 | $312 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $306 |
| Adlon Therapeutics L.p. | 14 | $209 |
| Bausch Health US, LLC | 7 | $149 |
| Lundbeck LLC | 7 | $141 |
| Corium, LLC | 6 | $130 |
| Indivior Inc. | 5 | $117 |
| Eisai Inc. | 6 | $113 |
| Almatica Pharma LLC | 3 | $87 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $84 |
| Tris Pharma Inc | 3 | $74 |
| Sage Therapeutics, LLC | 1 | $71 |
| Merck | 5 | $65 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Braeburn Inc. | 1 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,360 in reported general payments places this provider in the 85th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 12 | $4,570 |
| Lurasidone Hcl | 12 | $2,340 |
| Bupropion XlBupropion Hcl | 89 | $1,906 |
| Atomoxetine Hcl | 23 | $1,617 |
| Duloxetine Hcl | 96 | $1,539 |
| Trazodone Hcl | 76 | $921 |
| Methylphenidate Hcl | 17 | $591 |
| Oxcarbazepine | 16 | $577 |
| Buspirone Hcl | 55 | $500 |
| Alprazolam | 22 | $395 |
| Aripiprazole | 17 | $333 |
| Quetiapine Fumarate | 46 | $325 |
| Fluoxetine Hcl | 21 | $278 |
| Escitalopram Oxalate | 37 | $270 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $233 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Baltimore
- Akira SawaBaltimore$5.1M
- John VaethBaltimore$2.1M
- Paul RosenbergBaltimore$1.9M
- Scott AaronsonBaltimore$1.3M
- Karen AndersonBaltimore$1.1M
- Constantine LyketsosBaltimore$1.1M
- Alan JonasBaltimore$1.1M
- Sarah HertsBaltimore$1M
- Robert LehmanBaltimore$947K
- Marc FishmanBaltimore$822K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.